Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 0 · FY2024 0
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company carries out wholesale trade in pharmaceuticals and computer equipment.
Group parent — controls 2 companies · ownership
| Line item | 2020 | 2021 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Total Revenue | 11,143 | 19,223 | 5,128 | 345 | -58.1% |
| Total COGS | 9,806 | 3,897 | 557 | 183 | -63.1% |
| Gross Profit | 1,338 | 15,326 | 4,571 | 162 | -41.0% |
| Gross Margin | 12.0% | 79.7% | 89.1% | 47.0% | |
| 454 | 2,996 | 5,164 | 127 | -27.2% | |
| EBITDA | 884 | 12,330 | 594 | 35 | -55.4% |
| EBITDA Margin | 7.9% | 64.1% | 11.6% | 10.1% | |
| Total D&A | 37 | 105 | 433 | 0 | +126.3% |
| EBIT / Operating Income | 847 | 12,225 | 1,026 | 35 | -54.9% |
| Total Interest Expense | 29 | 132 | 0 | 0 | +352.8% |
| Total Other Income | 90 | 65 | 2,768 | 0 | nmf |
| Profit Before Tax | 727 | 12,028 | 1,741 | 35 | -53.2% |
| Total Income Tax | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 727 | 12,028 | 1,741 | 35 | -53.2% |
| Net Margin | 6.5% | 62.6% | 34.0% | 10.1% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.